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Original Article
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ABSTRACT
In clinical practice, evaluation of clinical efficacy of treatment planning stems from the radiation oncologist’s experience
in accurately targeting tumors, while keeping minimal toxicity to various organs at risk (OAR) involved. A more objective,
quantitative method may be raised by using radiobiological models. The purpose of this work is to evaluate the potential
correlation of OAR-related toxicities to its radiobiologically estimated parameters in simultaneously integrated boost (SIB)
intensity modulated radiation therapy (IMRT) plans of patients with head and neck tumors at two institutions. Lyman model for
normal tissue complication probability (NTCP) and the Poisson model for tumor control probability (TCP) models were used
LQ WKH +LVWRJUDP $QDO\VLV LQ 5DGLDWLRQ 7KHUDS\ +$57  DQDO\VLV ,Q WKLV VWXG\  SDWLHQWV ZLWK RURSKDU\QJHDO SULPDULHV LQ
the head and neck region were used to establish the correlation between NTCP values of (a) bilateral parotids with clinically
observed rates of xerostomia, (b) esophagus with dysphagia, and (c) larynx with dysphagia. The results of the study indicated
a strong correlation between the severity of xerostomia and dysphagia with Lyman NTCP of bilateral parotids and esophagus,
respectively, but not with the larynx. In patients without complications, NTCP values of these organs were negligible. Using
appropriate radiobiological models, the presence of a moderate to strong correlation between the severities of complications
with NTCP of selected OARs suggested that the clinical outcome could be estimated prior to treatment.
Key words: Dysphagia, head and neck cancers, normal tissue complication probability, radiobiology, xerostomia

Introduction
Treatment of head and neck cancers using intensity
modulated radiation therapy (IMRT) is a promising
technique due to its ability to conform high doses to
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irregularly shaped treatment volumes, and also the clever
use of inverse planning techniques to steer radiation doses
away from multiple critical normal organs. Two of the most
common complications associated with IMRT of head and
neck tumor treatments are xerostomia (inadequate and
even lack of salivary production) and dysphagia (increased
swallowing difficulty of the esophagus). While the former
is reported to be due to irradiation of parotid tissues,[1]
the latter is due to irradiation of pharyngeal constrictors,
esophagus, and larynx;[2] both processes are biologically
and physiologically complex.
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Lyman normal tissue complication probability (NTCP)
model is one of the most popular radiobiological models
typically used in modern dose-effect calculations.[3] This model
is based on calculated dose volume histograms (DVH) of the
organs at risk (OAR);[4-6] this work was detailed by Luxton et al.
who outlined the key values of the main parameters, namely
TD50,5, slope parameter (m), and the volume parameter (n).[7]
In this project, we introduced and evaluated the tumor control
probability (TCP) and NTCP values of multiple targets and
OARs, from their respective DVH statistics using the histogram
analysis in radiation therapy (HART) software.[8] The treatment
plans were clinically produced and strictly followed in regard to
organ tolerances as established by the quantitative analyses of
normal tissue effects in the clinic (QUANTEC) guidelines.[9]

Materials and Methods
Patient population
In this study, we focused on the toxicities observed in
parotids, esophagus, and larynx. IMRT plans of the head
and neck cancers were retrospectively reviewed in this study,
which was approved by the Institutional Review Board at
both institutions (Institutions 1, 2). Between 2009 and
2011, 95 consecutive patients with oropharyngeal primaries
were identified. Accessibility of the treatment plan and the
follow-up data limited the available pool to 61 patients.
Among these patients who received IMRT due to head and
neck cancers, 33 (54%) cases whom developed clinically
significant xerostomia (N = 23), dysphagia (N = 22),
or both complications (N = 12) in the long-term were
studied. All patients were treated using simultaneously
integrated boost (SIB) technique; these 33 cases formed
the cohort of this study. The mean age was 68 years (range:
55–82 years). The follow-up time ranged from 1.5 to
3.0 years from the end of treatment, with a mean of
2.1 years. Free-breathing computed tomography (CTs) were
acquired on a GE-LightSpeed 16-slice CT scanner (GE
Healthcare, Waukesha, WI), and immobilization was
generally acquired by the use of a thermoplastic mask. The
patients were treated using a 6MV photon beam from 23EX
linear accelerator (Varian Medical Systems, Palo Alto, CA,
USA) with a multi-leaf collimator having 60 pairs of leaves.
Nine (9) patients were treated using volumetric modulated
arc therapy (VMAT) with two opposing arcs at a maximum
dose rate of 600 MU/min. The remaining 24 cases were
treated using 7–9 step and shoot IMRT beams in coplanar
or noncoplanar configuration. The 33 patients were treated
with the prescription dose (PD) ranging between 63.0 and
70.2 Gy (average, 69.0 Gy) over 29–39 fractions (average,
34 fractions). Up to 3 SIB-based target volumes (PTV1,
PTV2, and PTV3) were delineated [Figure 1]. The mean
value ± standard deviation of PTV1, PTV2, and PTV3 were
317.0 ± 252.4 cc, 524.7 ± 359.7 cc, and 282.6 ± 121.8 cc,
respectively. The Pinnacle TPS (ver. 7.6c, Philips Healthcare,
The Netherlands) and XiO TPS (ver. 4.50, CMS, St Louis,
Journal of Medical Physics, Vol. 40, No. 3, 2015

Figure 1: Transverse, sagittal, and coronal slices of computed tomography
images of a patient with head and neck cancer treated by simultaneously
integrated boost intensity modulated radiation therapy. In this particular
example, three (3) PTV levels in yellow, green and orange receiving 5445,
5940 and 6996 cGy were shown, respectively

USA) were used for treatment planning. The OARs included
the parotid glands, nasopharynx, larynx, mandibles, optic
structures, brainstem, spinal cord, brachial plexus, and whole
brain. The treatment plan objectives were based on the
QUANTEC guidelines. The contours, field arrangement,
dose plan, and target conformity were approved by the
respective institutional prescribing radiation oncologists.
Complications
The severity of complications was graded using the
Common Terminology Criteria for Adverse Events guidelines
(CTCAE ver. 4.0).[10] National Cancer Institute- based
CTCAE has been widely accepted across the oncology
community as the standard for adverse event grading.
While grades 1, 2, and 3 stands for mild, moderate and
severe symptoms, grades 4 and 5 are typically related to
life-threatening consequences and death from the inciting
adverse events, respectively. There was no grade 5 toxicity
recorded in this study.
Radiobiological modeling
The TCP model predicts that cell killing is based on Poisson
statistics. For a given heterogeneous dose distribution
defined by discrete DVH (dDVH) values {Di, vi}, TCP is
given by the following expression:[11]
ª
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Where, TCD50 is the dose producing 50% TCP and J50 is
the normalized slope at the 50% probability level. The PD
considered in this study was the largest dosage prescribed to
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the PTVs. In TCP computation, the range of the reference
values of Di used to estimate normalized volume (vi) was
20%PD, 40% PD, 60% PD, 80% PD, 100% PD, 110% PD,
and 120% PD.
The Lyman NTCP model for normal tissue irradiation
was based on the sigmoidal dose-response relationship and
the equivalent uniform dose (EUD) concept:
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The reference values of Di used to estimate vi in Lyman
NTCP estimation were 25% PD, 50% PD, 75% PD,
100% PD. The parameter m indicated the slope of the
dose-response curve, and TD50 determined the position of a
dose-response curve at the 50% probability of complication.
EUD, or generalized equivalent uniform dose (gEUD),
represented the uniform dose that would produce the same
radiobiological effect as the given heterogeneous dose
specified by the DVH.[12]
1 ·n
§
gEUD ¨ ¦ vi Di n ¸
(3)
©i
¹

HART program. CT slice of a representative patient with the
highest PD of 69.96 Gy which was treated using VMAT is
shown in Figure 1. The reference values of dose and fractional
volumes used in computation of NTCP value of parotid
glands of the representative patient were: (1749 cGy, 0.745),
(3498 cGy, 0.517), (5247 cGy, 0.37), and (6996 cGy, 0.156).
The patient had a NTCP value of 0.71 of parotid glands,
and xerostomia severity of 2 by grade. Values were quoted as
mean ± standard error at 95% confidence level (SE). For the
patient population studied (N = 33), the mean ± SE TCP
value was estimated to be 0.8 ± 0.03; while the NTCP values
of the parotids, esophagus and larynx were 0.4 ± 0.1, 0.2 ± 0.1,
and 0.1 ± 0.1, respectively. The PD ranged between 63.0 and
70.2 Gy (mean dose prescribed was 69.0 Gy).
The severity of xerostomia was found to correlate
well with the NTCP value of parotids, with a correlative
strength of 0.63 (Pearson correlation coefficient value, R2),
as shown in Figure 2a. Using a paired two-tailed Student’s
t-test, statistical significant difference was observed
with P < 0.01. The correlation between the severity of
dysphagia and NTCP value of esophagus was also found
to be statistically significant, with P < 0.01 and R2 = 0.74
indicating strong correlation, as shown in Figure 2b. The
solid line shows the best fit of the severity of complications
with the NTCP values based on the available data; the line
of best fit equations were measured at y = 1.38x + 0.89 for

Whereas, {Di, vi} were the dose-volume values in the
dDVH and n determined the dose-volume dependence of a
tissue which was deterministic based on tissue architecture
differences.
The values that were used in this study for calculation
of TCP and NTCP were obtained from Luxton et al.[7]
For tumor control, TCD50 = 63.8 Gy, and D/E=10 Gy. For
bilateral parotids, TD50,5 = 28.4 Gy, m = 0.18, and n = 1
were applied. For esophagus, TD50,5 = 47 Gy, m = 0.36, and
n = 0.69. Finally, for larynx, TD50,5 = 70 Gy, m = 0.17 and
n = 0.08. The HART computational platform was used for
calculating the TCP and NTCP values from DVH. The
NTCP values of the three OARs reported above (calculated
from HART program) were used to correlate toxicity levels
which led to complications.[8]

a

As a baseline measurement, the NTCP values of the
parotids, esophagus, and larynx were estimated for the
remainder of the patient population without any reported
long-term xerostomia or dysphagia complications.

Results
In the 33 IMRT head and neck cancer cases, the TCP and
NTCP values were derived from the DVH statistics using

b
Figure 2: Correlation between the severity of (a) xerostomia and (b)
dysphagia with the Lyman normal tissue complication probability indices
of bilateral parotid glands for TD50,5 = 28.4 Gy (R2 = 0.63, P < 0.01) and
esophagus for TD50,5 = 47Gy (R2 = 0.74, P < 0.01), respectively
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xerostomia, and y = 5.75x + 0.89 for dysphagia, where y
represents the severity of complication by grade, and x being
the calculated NTCP values. However, the Lyman model
provided a very poor correlation between dysphagia severity
and NTCP of the larynx (R2 = 0.01, which indicated a poor
level of correlation). In addition, no correlation was found
between the complication severity and the PD or DVH
values for any of the three organs.
In a sub-group study of 15 patients treated at higher PDs
of 70 ± 0.3 Gy, grade 2 + xerostomia, and 3 + dysphagia
toxicities were observed in 9 and 7 patients, respectively. In
this sub-group, the corresponding mean ± SE NTCP values
were 0.7 ± 0.1 (N = 15) for parotids and 0.4 ± 0.04 (N = 15)
for esophagus, respectively.
From the baseline study on patients without any report
of xerostomia or dysphagia complications, the mean ± SE
values of NTCP of parotids, esophagus and larynx were
found to be 0.06 ± 0.03, 0.05 ± 0.02, and 0.04 ± 0.04,
respectively. The mean ± SE TCP value was estimated to
be 0.75 ± 0.05.

Discussion
The IMRT dosimetric planning objectives of head and
neck tumors were similar across patients and followed
the guidelines outlined in QUANTEC.[9] However, the
radiation-related complications which occurred in patients
may depend on various dosimetric and radiobiological
factors including the spatial distance of OAR’s from the
tumor, beam weighting, and OAR classification based on
functional subunits; it is certainly multifactorial across a
number of different domains in the realms of clinical and
biological radiation oncology.
Our study looked at a few complications that were prevalent
among the head and neck tumor patients who received IMRT.
A pattern of correlation was identified between the severity
of complications and the NTCP of three organs of interest.
Among the three possible correlations, only 2 (xerostomia
and dysphagia for parotid and esophageal toxicities,
respectively) were considered significant on the two-tailed
Student’s t-test and the Pearson correlation coefficients;
however, the number of cases in this study were limited.
Among the patients with neither of the two complications,
NTCP of the three OARs were found to be negligible. The
correlation between the corresponding toxicities and NTCPs
of the examined OARs depends on the availability of the
proper dosimetric information and the accuracy of clinical
follow-up data on the reported toxicity levels.
A multicenter study showed that among many factors,
the mean parotid dose was the most important predictor of
moderate to severe xerostomia at 6 months.[13] However, no
long term toxicity data were mentioned in their work. Roesnik
Journal of Medical Physics, Vol. 40, No. 3, 2015

et al. modeled the reduction of individual parotid flow rates
using the LKB model.[14] Many studies demonstrated that
the salivary flow could be reduced exponentially with a mean
parotid gland threshold dose above 26 Gy.[15,16] Quantitative
models describing the reduction of the parotid function
with the dose distribution over the major and minor salivary
glands were previously reported.[17-19]
Increased dose to a large volume of swallowing structures
is reported to result in higher levels of dysphagia in a number
of studies.[20-22] In a study on 82 head and neck tumor patients
treated with SIB-IMRT, long term dysphagia was related to
radiation dose delivered to the swallowing structures.[23]
Taking into account the complex sequence of swallowing
event, it is highly unlikely a single structure is important.
Even though xerostomia can be reduced with parotid-sparing
IMRT, the comparable advances in successful reduction of
dysphagia toxicities have been largely limited.

Conclusion
This study suggested that a moderate to strong correlation
may exist between the severities of xerostomia and also
dysphagia, with the calculated NTCP values of bilateral
parotids and esophagus as OARs, respectively. The existence
of a reasonable degree of correlation between the observed
complication rates and NTCP values demonstrates that
clinically apparent complications or side effects may
be further improved by using selective radiobiological
parameters in radiotherapy planning that are directly
derived from appropriate models.
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